Biolinq Secures $100M in Series C Funding for Innovative Glucose Sensor Patch

Biolinq, a pioneering medtech company, has successfully raised $100 million in a Series C financing round to advance the development and commercialization of its revolutionary wearable glucose biosensor. The funding, led by Alpha Wave Ventures, marks a significant milestone in the company's journey towards bringing its innovative technology to market.

Cutting-Edge Wearable Technology

The coin-sized device, designed to be worn on the forearm, represents a leap forward in glucose monitoring technology. Unlike traditional glucose monitors, Biolinq's biosensor employs an array of electrochemical sensors capable of measuring multiple analytes beneath the skin without the need for introducer needles or subcutaneous tissue access.

The device's capabilities extend beyond glucose monitoring, offering sleep and activity tracking to provide a more comprehensive view of the user's metabolic health. A color-changing indicator light provides real-time feedback on blood sugar levels, enhancing user experience and ease of use.

Financial Backing and Commercial Prospects

The latest funding round brings Biolinq's total capital raised to an impressive $258 million over the past four years. This includes a $58 million raise in April 2024 and a $100 million Series B round in late 2021, both led by Alpha Wave Ventures.

Dan Bradbury, Biolinq's chairman, expressed optimism about the technology's potential, stating, "Biolinq is unlocking a new era of biosensing technology, making glucose information simpler and more accessible. This technology has the potential to help restore metabolic health for millions of people living with Type 2 diabetes not using insulin."

Regulatory Approval and Future Plans

With the new influx of capital, Biolinq is poised to complete the development of its wearable glucose biosensor and prepare for submissions to obtain U.S. regulatory approval. The funding will also support the company's commercial efforts as it gears up for market entry.

Rick Gerson, chairman of Alpha Wave Global, previously highlighted the company's ability to attract leading experts in various fields, including biosensor development, consumer electronics design, proprietary materials science, software engineering, and semiconductor manufacturing. This diverse expertise positions Biolinq to potentially create a new category of biowearables, revolutionizing the way metabolic health is monitored and managed.